{"id":344943,"date":"2025-08-26T10:32:11","date_gmt":"2025-08-26T10:32:11","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/344943\/"},"modified":"2025-08-26T10:32:11","modified_gmt":"2025-08-26T10:32:11","slug":"a-rennes-vitadx-leve-15-me-pour-son-dispositif-de-diagnostic-du-cancer-de-la-vessie","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/344943\/","title":{"rendered":"\u00c0 Rennes, VitaDX l\u00e8ve 1,5 M\u20ac pour son dispositif de diagnostic du cancer de la vessie"},"content":{"rendered":"<p>Bas\u00e9e \u00e0 Rennes, l\u2019entreprise VitaDX a d\u00e9velopp\u00e9 <a href=\"https:\/\/www.letelegramme.fr\/ille-et-vilaine\/rennes-35000\/cancer-le-rennais-vitadx-se-lance-a-lassaut-du-marche-americain-6461501.php\" target=\"_blank\" rel=\"noopener\">un logiciel d\u2019intelligence artificielle, VisioCyt Bladder<\/a>, qui doit permettre de mieux diagnostiquer les cancers de la vessie. Pour poursuivre son d\u00e9veloppement, la soci\u00e9t\u00e9 annonce avoir lev\u00e9 1,5 M\u20ac aupr\u00e8s de ses investisseurs historiques, dont Go Capital et Odyss\u00e9e Venture, et de nouveaux investisseurs. La derni\u00e8re op\u00e9ration en date remonte au printemps 2024, avec 6,5 M\u20ac lev\u00e9s. VitaDx, qui compte une vingtaine de salari\u00e9s, annonce aussi le recrutement de Fabrice Beauch\u00eane \u00e0 la direction g\u00e9n\u00e9rale. Allan Rodriguez c\u00e8de donc la direction et devient pr\u00e9sident du conseil d\u2019administration.<\/p>\n<p>Avec les nouveaux fonds et l\u2019arriv\u00e9e d\u2019un nouveau directeur, la PME veut avoir les moyens de poursuivre la commercialisation de VisioCyt Bladder, qui a d\u00e9but\u00e9 en France en 2023 mais devrait acc\u00e9l\u00e9rer avec une inscription au remboursement attendue en septembre prochain. La Haute Autorit\u00e9 de sant\u00e9 (HAS) a donn\u00e9 son feu vert \u00e0 ce remboursement (dans un cadre d\u00e9rogatoire) dans <a href=\"https:\/\/www.has-sante.fr\/jcms\/p_3609087\/en\/avis-n2025-0027\/ac\/seap-du-5-juin-2025-du-college-de-la-has-relatif-a-la-prise-en-charge-derogatoire-de-l-acte-de-cytologie-urinaire-digitalisee-et-assistee-par-intelligence-artificielle-impliquant-le-dispositif-medical-de-diagnostic-in-vitro-visiocyt-bladder-en-application-de-l-article-l-162-1-24-du-css\" target=\"_blank\" rel=\"noopener\">un avis<\/a> rendu en juin dernier. VitaDx pr\u00e9pare aussi le lancement commercial de son produit aux \u00c9tats-Unis et r\u00e9fl\u00e9chit \u00e0 de nouvelles utilisations, notamment dans le cancer de la thyro\u00efde.<\/p>\n","protected":false},"excerpt":{"rendered":"Bas\u00e9e \u00e0 Rennes, l\u2019entreprise VitaDX a d\u00e9velopp\u00e9 un logiciel d\u2019intelligence artificielle, VisioCyt Bladder, qui doit permettre de mieux&hellip;\n","protected":false},"author":2,"featured_media":344944,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2821],"tags":[1111,11,829,1777,674,1011,27,848,4555,12,584,25],"class_list":{"0":"post-344943","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-rennes","8":"tag-actu","9":"tag-actualites","10":"tag-bretagne","11":"tag-eu","12":"tag-europe","13":"tag-fr","14":"tag-france","15":"tag-ille-et-vilaine","16":"tag-local","17":"tag-news","18":"tag-rennes","19":"tag-republique-francaise"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115094614439522799","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/344943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=344943"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/344943\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/344944"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=344943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=344943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=344943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}